NRBO NeuroBo Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NRBO

Price (delayed)

$3.06

Market cap

$15.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.46

Enterprise value

-$7.22M

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of 4 drug candidates. The ...

Highlights
The debt fell by 7% QoQ
The EPS has shrunk by 106% QoQ but it has soared by 94% YoY
The quick ratio rose by 33% year-on-year but it has declined by 31% since the previous quarter
The equity has declined by 23% year-on-year and by 23% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.neurobopharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of NRBO
Market
Shares outstanding
4.91M
Market cap
$15.01M
Enterprise value
-$7.22M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.89
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$12.47M
EBITDA
-$12.46M
Free cash flow
-$10.85M
Per share
EPS
-$2.46
Free cash flow per share
-$2.14
Book value per share
$3.44
Revenue per share
$0
TBVPS
$4.49
Balance sheet
Total assets
$22.78M
Total liabilities
$6.1M
Debt
$203,000
Equity
$16.69M
Working capital
$16.55M
Liquidity
Debt to equity
0.01
Current ratio
3.78
Quick ratio
3.76
Net debt/EBITDA
1.78
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-45.4%
Return on equity
-59.4%
Return on invested capital
N/A
Return on capital employed
-74.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NRBO stock price

How has the NeuroBo Pharmaceuticals stock price performed over time
Intraday
-1.29%
1 week
-10%
1 month
-30.22%
1 year
-43.25%
YTD
-17.22%
QTD
-25.18%

Financial performance

How have NeuroBo Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$15.89M
Net income
-$12.47M
Gross margin
N/A
Net margin
N/A
NRBO's operating income is up by 23% from the previous quarter and by 19% YoY
The company's net income rose by 11% YoY but it fell by 5% QoQ

Growth

What is NeuroBo Pharmaceuticals's growth rate over time

Valuation

What is NeuroBo Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.89
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has shrunk by 106% QoQ but it has soared by 94% YoY
The P/B is 85% below the 5-year quarterly average of 5.8 but 11% above the last 4 quarters average of 0.8
The equity has declined by 23% year-on-year and by 23% since the previous quarter

Efficiency

How efficient is NeuroBo Pharmaceuticals business performance
The ROE rose by 48% YoY but it fell by 12% QoQ
The ROA has grown by 47% YoY but it has contracted by 16% from the previous quarter

Dividends

What is NRBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NRBO.

Financial health

How did NeuroBo Pharmaceuticals financials performed over time
The total liabilities has declined by 48% year-on-year but it rose by 25% since the previous quarter
The quick ratio rose by 33% year-on-year but it has declined by 31% since the previous quarter
The debt is 99% lower than the equity
The equity has declined by 23% year-on-year and by 23% since the previous quarter
The debt fell by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.